TABLE 2.
Summary of pooled odds ratios of variables associated with significant liver fibrosis.
| Variables | Pooled OR (95% CI) | I 2 | References | Number of patients |
| Age | 2.20 (1.42–3.40) | 0% | (31, 38, 44, 45) | 344 |
| Male | 1.10 (0.87–1.39) | 3.2% | (27, 29, 31, 35, 36, 38, 39, 41, 42, 44–46) | 1,851 |
| PASI > 10 | 1.67 (0.94–2.95) | 37% | (27, 31, 41, 46) | 500 |
| Psoriatic arthritis | 1.30 (0.82–2.06) | 30.6% | (27, 35, 36, 46) | 738 |
| Cumulative MTX dose >1500 mg | 1.58 (0.91–2.75) | 0% | (29, 39, 45, 46) | 422 |
| BMI > 30 | 3.67 (2.37–5.68) | 48.8% | (27, 31, 36, 41, 44) | 602 |
| Diabetes mellitus | 6.23 (4.39–8.84) | 42.4% | (27, 31, 35, 36, 41, 44–46) | 1,200 |
| Hypertension | 2.82 (1.68–4.74) | 0% | (27, 41, 45, 46) | 409 |
| Dyslipidemia | 3.08 (1.90–4.98) | 0% | (27, 31, 41, 45, 46) | 541 |
| Metabolic syndrome | 5.98 (3.63–9.83) | 17% | (35, 39, 41, 45, 46) | 768 |
BMI, body mass index; MTX, methotrexate; OR, odds ratio; PASI, psoriasis area severity index.